AAAAAA

   
Results: 1-18 |
Results: 18
Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines
Authors: Adjei, AA Davis, JN Bruzek, LM Erlichman, C Kaufmann, SH
Citation: Aa. Adjei et al., Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines, CLIN CANC R, 7(5), 2001, pp. 1438-1445
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
Authors: Alberts, SR Erlichman, C Sloan, J Okuno, SH Burch, PA Rubin, J Pitot, HC Goldberg, RM Adjei, AA Atherton, PJ Kaufmann, SH
Citation: Sr. Alberts et al., Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks, ANN ONCOL, 12(5), 2001, pp. 627-631
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2 '-deoxyuridine (IdUrd)
Authors: Galanis, E Goldberg, R Reid, J Atherton, P Sloan, J Pitot, H Rubin, J Adjei, AA Burch, P Safgren, SL Witzig, TE Ames, MM Erlichman, C
Citation: E. Galanis et al., Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2 '-deoxyuridine (IdUrd), ANN ONCOL, 12(5), 2001, pp. 701-707
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
Authors: Erlichman, C Adjei, AA Alberts, SR Sloan, JA Goldberg, RM Pitot, HC Rubin, J Atherton, PJ Klee, GG Humphrey, R
Citation: C. Erlichman et al., Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566, ANN ONCOL, 12(3), 2001, pp. 389-395
Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide
Authors: Sloan, JA Atherton, P Reid, J Pilot, HC Erlichman, C Schaaf, L
Citation: Ja. Sloan et al., Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide, CANC CHEMOT, 48(3), 2001, pp. 241-249
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
Authors: Erlichman, C Goldberg, RM O'Connell, MJ
Citation: C. Erlichman et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, N ENG J MED, 344(4), 2001, pp. 305-305
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistanceprotein-mediated drug efflux
Authors: Erlichman, C Boerner, SA Hallgren, CG Spieker, R Wang, XY James, CD Scheffer, GL Maliepaard, M Ross, DD Bible, KC Kaufmann, SH
Citation: C. Erlichman et al., The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistanceprotein-mediated drug efflux, CANCER RES, 61(2), 2001, pp. 739-748
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
Authors: Pitot, HC Goldberg, RM Reid, JM Sloan, JA Skaff, PA Erlichman, C Rubin, J Burch, PA Adjei, AA Alberts, SA Schaaf, LJ Elfring, G Miller, LL
Citation: Hc. Pitot et al., Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy, CLIN CANC R, 6(6), 2000, pp. 2236-2244
Comparison of potential markers of farnesyltransferase inhibition
Authors: Adjei, AA Davis, JN Erlichman, C Svingen, PA Kaufmann, SH
Citation: Aa. Adjei et al., Comparison of potential markers of farnesyltransferase inhibition, CLIN CANC R, 6(6), 2000, pp. 2318-2325
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
Authors: Adjei, AA Erlichman, C Sloan, JA Reid, JM Pitot, HC Goldberg, RM Peethambaram, P Atherton, P Hanson, LJ Alberts, SR Jett, J
Citation: Aa. Adjei et al., Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors, J CL ONCOL, 18(8), 2000, pp. 1748-1757
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity
Authors: Adjei, AA Klein, CE Kastrissios, H Goldberg, RM Alberts, SR Pitot, HC Sloan, JA Reid, JM Hanson, LJ Atherton, P Rubin, J Erlichman, C
Citation: Aa. Adjei et al., Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity, J CL ONCOL, 18(5), 2000, pp. 1116-1123
More patients needed in stage II Colon Cancer Trials - In reply
Authors: Erlichman, C
Citation: C. Erlichman, More patients needed in stage II Colon Cancer Trials - In reply, J CL ONCOL, 18(1), 2000, pp. 236-236
Metastatic non-small cell lung carcinoma with involvement of extremity musculature: Case report and review of the literature
Authors: Ramakrishna, G Harms, GF Erlichman, C
Citation: G. Ramakrishna et al., Metastatic non-small cell lung carcinoma with involvement of extremity musculature: Case report and review of the literature, MAYO CLIN P, 75(12), 2000, pp. 1333-1337
A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
Authors: Adjei, AA Erlichman, C Davis, JN Cutler, DL Sloan, JA Marks, RS Hanson, LJ Svingen, PA Atherton, P Bishop, WR Kirschmeier, P Kaufmann, SH
Citation: Aa. Adjei et al., A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity, CANCER RES, 60(7), 2000, pp. 1871-1877
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors
Authors: Pitot, HC McElroy, EA Reid, JR Windebank, AJ Sloan, JA Erlichman, C Bagniewski, PG Walker, DL Rubin, J Goldberg, RM Adjei, AA Ames, MM
Citation: Hc. Pitot et al., Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors, CLIN CANC R, 5(3), 1999, pp. 525-531
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
Authors: Erlichman, C O'Connell, M Kahn, M Marsoni, S Torri, V Tardio, B Zaniboni, A Pancera, G Martignoni, G Labianca, R Barni, A Seitz, JF Milan, C Bedenne, L Giovannini, M Letreut, YP Skillings, J Shepard, L Zee, B Petrioli, R Francini, G
Citation: C. Erlichman et al., Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer, J CL ONCOL, 17(5), 1999, pp. 1356-1363
Optimum doses of irinotecan
Authors: Erlichman, C Goldberg, RM Pitot, HC O'Connell, MJ
Citation: C. Erlichman et al., Optimum doses of irinotecan, LANCET, 353(9160), 1999, pp. 1275-1276
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer
Authors: Adjei, AA Erlichman, C
Citation: Aa. Adjei et C. Erlichman, A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer, SEMIN ONCOL, 26(2), 1999, pp. 94-98
Risultati: 1-18 |